论文部分内容阅读
据日本藤泽药厂在第15届世界抗菌剂和化疗剂会议上提出的报告声称:该公司已试制成功一种新的β-内酯胺抗菌素,名为FR-1923,这是一种单环型β-内酰胺,具有一个新的酰胺侧链,但它与青霉素和头孢菌素不同,前者是以五员噻唑烷环与β-内酰胺稠合,后者则是以六员的双氢噻嗪与β-内酰胺稠合的。据该厂研究人员说,FR-1923对β-内酰胺酶较稳定,不象青霉素和头孢菌素那样易被钝化,且对实验动物来说,其体内抗菌活性,还比体外抗菌活性来得更强一些。
According to reports by Japan’s Fujisawa Pharmaceuticals at the 15th World Conference on Antibacterial and Chemotherapeutic Agents, the company has trial-produced a new beta-lactonamide antibiotic called FR-1923, a single Ring-type β-lactam, with a new amide side chain, but it is different from penicillin and cephalosporin, the former is five-member thiazolidine ring and β-lactam fusion, the latter is based on a six-member double Hydrothiazine and β-lactam fused. According to the plant researchers, FR-1923 is more stable to beta-lactamase, less susceptible to passivation than penicillins and cephalosporins, and has an antibacterial activity in vivo that is more potent than in vitro antibacterial activity Stronger.